Organogenesis Holdings Inc. (ORGO) Bundle
A Brief History of Organogenesis Holdings Inc. (ORGO)
Company Overview
Organogenesis Holdings Inc. (NASDAQ: ORGO) is a commercial-stage regenerative medicine company focused on developing, manufacturing, and marketing advanced wound care and surgical biologics products.
Financial Performance
| Fiscal Year | Revenue | Net Income | Stock Price (as of Q4 2023) |
|---|---|---|---|
| 2022 | $397.6 million | $29.1 million | $3.52 |
| 2023 | $434.2 million | $35.7 million | $4.15 |
Product Portfolio
- Affinity Wound Care Product Line
- Omnigen Surgical Biologics
- PuraPly Wound Healing Products
Key Product Performance
| Product | 2022 Sales | 2023 Sales | Growth Percentage |
|---|---|---|---|
| PuraPly | $187.3 million | $212.6 million | 13.5% |
| Affinity | $98.5 million | $115.4 million | 17.2% |
Corporate Metrics
- Total Employees: 628
- Research & Development Spending: $45.2 million (2023)
- Market Capitalization: $422 million (December 2023)
Geographic Revenue Distribution
| Region | 2023 Revenue | Percentage of Total |
|---|---|---|
| United States | $392.1 million | 90.3% |
| International Markets | $42.1 million | 9.7% |
A Who Owns Organogenesis Holdings Inc. (ORGO)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| BlackRock Inc. | 2,456,721 | 9.42% |
| Vanguard Group Inc. | 1,987,345 | 7.61% |
| Perceptive Advisors LLC | 1,543,210 | 5.91% |
Insider Ownership
- Gary S. Gillheeney Sr. (President & CEO): 532,000 shares
- Michael Piazza (Chief Financial Officer): 124,500 shares
- Other Executive Officers: 287,600 shares combined
Top Institutional Investors
Percentage of Total Institutional Ownership: 65.3%
| Investor | Shares | Value ($) |
|---|---|---|
| Millennium Management LLC | 1,345,678 | $15,234,567 |
| Orbimed Advisors LLC | 987,654 | $11,876,543 |
Ownership Structure
Public Float: 26,105,000 shares
- Institutional Investors: 65.3%
- Insider Ownership: 3.2%
- Retail Investors: 31.5%
Organogenesis Holdings Inc. (ORGO) Mission Statement
Company Overview
Organogenesis Holdings Inc. (ORGO) is a commercial-stage regenerative medicine company focused on advanced wound care and surgical biologics.
Financial Performance
| Metric | 2023 Value |
|---|---|
| Revenue | $428.1 million |
| Net Income | $35.3 million |
| Gross Margin | 68.3% |
Key Product Lines
- Advanced Wound Care Solutions
- Surgical Biologics
- Regenerative Medicine Products
Strategic Focus Areas
Primary Strategic Objectives:
- Expand regenerative medicine technology
- Develop innovative wound healing solutions
- Enhance surgical biologics portfolio
Market Positioning
| Market Segment | Market Share |
|---|---|
| Advanced Wound Care | 8.5% |
| Surgical Biologics | 6.2% |
Research and Development
R&D Investment in 2023: $47.6 million
Corporate Headquarters
Canton, Massachusetts
Stock Information
| Stock Symbol | Exchange | Price (as of January 2024) |
|---|---|---|
| ORGO | NASDAQ | $4.25 |
How Organogenesis Holdings Inc. (ORGO) Works
Company Overview
Organogenesis Holdings Inc. is a commercial-stage regenerative medicine company headquartered in Canton, Massachusetts. As of 2024, the company focuses on developing, manufacturing, and marketing regenerative medical products.
Product Portfolio
| Product Category | Key Products | Primary Application |
|---|---|---|
| Wound Care | Apligraf, PuraPly | Diabetic foot ulcers, venous leg ulcers |
| Surgical | PuraPly AM, PuraPly XT | Surgical wound repair |
| Skin Substitutes | Dermagraft | Diabetic foot ulcer treatment |
Financial Performance
Financial data for Organogenesis Holdings Inc. as of Q4 2023:
- Annual Revenue: $441.3 million
- Net Income: $23.6 million
- Gross Margin: 68.3%
- Operating Expenses: $294.7 million
Market Distribution
The company operates primarily in the United States healthcare market, with products distributed through:
- Direct sales force
- Healthcare distributors
- Wound care clinics
- Hospitals
Research and Development
R&D investment in 2023: $86.4 million, representing 19.6% of total revenue.
Stock Performance
| Stock Symbol | NASDAQ: ORGO |
|---|---|
| Share Price (February 2024) | $3.42 |
| Market Capitalization | $472 million |
Manufacturing Capabilities
Production facilities located in:
- Canton, Massachusetts
- Waltham, Massachusetts
Employee Count
Total employees: 697 (as of December 31, 2023)
How Organogenesis Holdings Inc. (ORGO) Makes Money
Revenue Streams
Organogenesis Holdings Inc. generates revenue through two primary business segments:
- Advanced Wound Care
- Surgical and Sports Medicine
Advanced Wound Care Segment
Revenue sources include:
| Product Line | 2023 Revenue |
|---|---|
| Apligraf Wound Care | $138.7 million |
| PuraPly Wound Care | $82.3 million |
Surgical and Sports Medicine Segment
Key revenue generating products:
- Affinity Membrane
- Omnigen Surgical Graft
| Product Category | 2023 Revenue |
|---|---|
| Surgical Products | $96.5 million |
| Sports Medicine Products | $45.2 million |
Financial Performance
2023 Financial Highlights:
- Total Revenue: $362.7 million
- Gross Margin: 63.4%
- Net Income: $24.1 million
Organogenesis Holdings Inc. (ORGO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.